iBio, Inc. (IBIO): R&D Expense
$19.64M
Year ended 2026-06-30
+23.9%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $19.64M | +136.3% | 2026-08-28, From 2025-07-01 |
| 2025-06-30 | $8.31M | +60.3% | 2026-08-28, From 2024-07-01 |
| 2024-06-30 | $5.18M | -49.8% | 2025-09-05, From 2023-07-01 |
| 2023-06-30 | $10.33M | +5.1% | 2024-09-24, From 2022-07-01 |
| 2022-06-30 | $9.83M | n/c | 2023-09-27, From 2021-07-01 |
| 2021-06-30 | $9.99M | +179.6% | 2022-10-11, From 2020-07-01 |
| 2020-06-30 | $3.57M | n/c | 2021-09-28, From 2019-07-01 |
| 2019-06-30 | $5.47M | +37.3% | 2020-10-13, From 2018-07-01 |
| 2018-06-30 | $3.99M | -3.2% | 2019-08-26, From 2017-07-01 |
| 2017-06-30 | $4.12M | +30.4% | 2018-09-18, From 2016-07-01 |
| 2016-06-30 | $3.16M | -9.7% | 2017-09-15, From 2015-07-01 |
| 2015-06-30 | $3.50M | +84.1% | 2016-10-13, From 2014-07-01 |
| 2014-06-30 | $1.90M | -44.7% | 2015-10-13, From 2013-07-01 |
| 2013-06-30 | $3.43M | -31.1% | 2014-09-29, From 2012-07-01 |
| 2012-06-30 | $4.98M | +61.5% | 2013-10-04, From 2011-07-01 |
| 2011-06-30 | $3.08M | n/a | 2012-10-15, From 2010-07-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| iBio, Inc. (IBIO) | 2026-06-30 | $19.64M | +136.3% |
| Actinium Pharmaceuticals, Inc. (ATNM) | 2025-12-31 | $21.12M | -29.7% |
| Incannex Healthcare Inc. (IXHL) | 2025-06-30 | $10.75M | -16.6% |
| BullFrog AI Holdings, Inc. (BFRG) | 2025-12-31 | $1.80M | -19.0% |
| Serina Therapeutics, Inc. (SER) | 2025-12-31 | $13.15M | +75.9% |
| Silo Pharma, Inc. (SILO) | 2025-12-31 | $2.16M | -8.8% |
| Inovio Pharmaceuticals, Inc. (INO) | 2025-12-31 | $54.21M | -28.3% |
| Connect Biopharma Holdings Ltd (CNTB) | 2025-12-31 | $37.80M | +29.2% |
| Avalo Therapeutics, Inc. (AVTX) | 2025-12-31 | $50.08M | +105.0% |
Compare IBIO, ATNM, IXHL, BFRG side by side · Screen every company in Pharmaceutical Preparations ↗